Last reviewed · How we verify
NCT05063968
A Clinical Trial of XZP-6019 Tablets in Healthy Subjects
Phase 1 trial testing XZP-6019 tablet in Non-alcoholic Fatty Liver Disease in 120 participants. Status unknown.
30 September 2022
Quick facts
| Lead sponsor | Xuanzhu Biopharmaceutical Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 120 |
| Start date | 30 November 2021 |
| Primary completion | 30 September 2022 |
| Estimated completion | 30 September 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- XZP-6019 tablet — full drug profile →
- Placebo
- XZP-6019 tablet — full drug profile →
- XZP-6019 tablet — full drug profile →
- XZP-6019 tablet — full drug profile →
- Placebo
Conditions studied
- Non-alcoholic Fatty Liver Disease — all drugs for Non-alcoholic Fatty Liver Disease →
Sponsor
Xuanzhu Biopharmaceutical Co., Ltd. — full company profile →
Who can join
Adults 18 to 45, any sex, with Non-alcoholic Fatty Liver Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will consist of 3 parts: Part A - Single Ascending Dose (SAD) phase, Part B - Food Effect (FE) phase, and Part C - multiple ascending dose (MAD) phase.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05063968
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non-alcoholic Fatty Liver Disease
Currently open trials in the same condition.
- NCT07358546 — A Study of Efimosfermin Alfa in Adults With Hepatic Impairment · Phase 1 · recruiting
- NCT07335198 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a · Phase 1 · recruiting
- NCT07221188 — A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or · Phase 3 · recruiting
- NCT07221227 — A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH · Phase 3 · recruiting
- NCT07514377 — JiGenerations Health Cohort Study：Parental Exposure and Intergenerational Health in China · active not recruiting
Other Xuanzhu Biopharmaceutical Co., Ltd. trials
Trials by the same sponsor.
- NCT07345689 — A Study of the Pharmacokinetics and Safety of Anaprazole Sodium in Special Populations · Phase 4 · not yet recruiting
- NCT07330531 — Drug-drug Interaction Study of Rifampin and Anaprazole Sodium · Phase 4 · not yet recruiting
- NCT05586568 — Drug-drug Interaction Study of XZP-3621 Tablet · Phase 1 · unknown
- NCT05478109 — A Clinical Trial of XZP-3287 for Material Balance · Phase 1 · unknown
- NCT05257395 — A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer · Phase 3 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05063968 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xuanzhu Biopharmaceutical Co., Ltd.
- Last refreshed: 1 October 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05063968.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing